These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21718321)

  • 1. PET/CT imaging in inflammatory myopathies.
    Al-Nahhas A; Jawad AS
    Ann N Y Acad Sci; 2011 Jun; 1228():39-45. PubMed ID: 21718321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging tools for the clinical assessment of idiopathic inflammatory myositis.
    Walker UA
    Curr Opin Rheumatol; 2008 Nov; 20(6):656-61. PubMed ID: 18946324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
    Schmidt GP; Kramer H; Reiser MF; Glaser C
    Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma.
    Okada M; Sato N; Ishii K; Matsumura K; Hosono M; Murakami T
    Radiographics; 2010; 30(4):939-57. PubMed ID: 20631361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Missed causative tumors in diagnosing tumor-induced osteomalacia with (18)F-FDG PET/CT: a potential pitfall of standard-field imaging.
    Kaneuchi Y; Hakozaki M; Yamada H; Hasegawa O; Tajino T; Konno S
    Hell J Nucl Med; 2016; 19(1):46-8. PubMed ID: 26929940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis.
    King AD; Ma BB; Yau YY; Zee B; Leung SF; Wong JK; Kam MK; Ahuja AT; Chan AT
    Br J Radiol; 2008 Apr; 81(964):291-8. PubMed ID: 18344274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes.
    Matsuhisa A; Toriihara A; Kubota K; Makino T; Mizusawa H; Shibuya H
    Clin Nucl Med; 2012 Jan; 37(1):39-43. PubMed ID: 22157026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pivotal role of FDG-PET/CT in modern medicine.
    Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
    Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of diffusion-weighted MRI with 18F-fluorodeoxyglucose-positron emission tomography/CT and electroencephalography in sporadic Creutzfeldt-Jakob disease.
    Xing XW; Zhang JT; Zhu F; Ma L; Yin DY; Jia WQ; Huang XS; Pu CQ; Lang SY; Yu SY
    J Clin Neurosci; 2012 Oct; 19(10):1354-7. PubMed ID: 22795494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
    J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone.
    Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S
    In Vivo; 2008; 22(4):513-7. PubMed ID: 18712181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implication of F-18 FDG PET/CT in patients with secondary hemophagocytic lymphohistiocytosis.
    Kim J; Yoo SW; Kang SR; Bom HS; Song HC; Min JJ
    Ann Hematol; 2014 Apr; 93(4):661-7. PubMed ID: 24061788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
    Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
    Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.